Member Info for kingskin

divide $96.11 by 12 = £8 then divide 8 by the exchange rate, at the mo is 1.32022 total = 6.06 the reason for the calculation is there are 12 ordinary shares in one ADR

divide by 12, then do the FX so its 606 simples ;)

bedrocan irradiate their product to ensure there are no moulds, thus making it more pharmaceutical grade (in theory) , i just wondered if tweed do so now.

not the 4th aug for LGS data, its September..still only weeks away though https://www.newcannabisventures.com/gw-pharma-epilepsy-research-in-australia-receives-6mm-government-funding-support/

yep , feels like that cos its not moving, so will break one way or the other at some point. not long to wait now though.

i dunno, but this is interesting :0 http://www.documentarytube.com/videos/how-long-is-a-piece-of-string do tweed irradiate their produce now, or is it only the bedrocan arm that do?

am i correct in thinking that bedrocan got bought out out by CGC stevie? if so this seems a long way of going about things, instead of importing from bedrocan in the Netherlands they are going to export (presumably) the same thing from Canada.. http://hightimes.com/news/tweed-coming-to-a-german-pharmacy-near-you/ wonder how long it will be before they export to our shores?

no probs ;)

earnings and 2nd lot of LGS data, sometime around the 4th.

google is saying earnings are 4/8/2016, so its poss we get the LGS data then, but its only an estimate buddy ;)

no worries stevie, just had a busy day at work, the info is on page 20 i think.. " In March 2014, we commenced a larger placebo-controlled Phase 2 dose ranging trial of GWP42004. The primary objective of this trial is to compare the change in glycemic control in patients with type-2 diabetes when treated with one of three doses of GWP42004 or placebo as add-on therapy, to metformin with the primary endpoint being change from baseline to the end of treatment in mean glycosylated hemoglobin A1c (HbA1c) level. The safety and tolerability of GWP42004 compared with placebo will also be assessed. This trial is now completed and a preliminary analysis of the topline data shows that this trial did not meet its primary endpoint. The drug was well tolerated with no serious adverse events. We are undertaking further evaluation of the data to determine whether to pursue further development of GWP42004 within the field of type-2 diabetes. " http://ir.gwpharm.com/secfiling.cfm?filingID=1144204-16-112989&CIK=1351288

yeah i think q3 is correct!

we were waiting for the diabetes data , which they published in the prospectus, so could be said went under the radar, though i copied and pasted it here last week. as far as i am aware the next data will be LGS sometime, maybe someone here could be more specific as im too busy to check.

great thread title btw :)

which results stevie?

not looking so good now...plop.

looking good freddie

yep, never knew all that, interesting stuff.

dont the insurance peeps understand how dangerous it is? pmsl

nice one lol ;)